RAP-219

DRUG5 trials

Sponsors

Rapport Therapeutics Inc.

Conditions

Bipolar 1 DisorderEpilepsyFocal EpilepsyFocal Onset SeizureFocal Onset SeizuresFocal SeizureRefractory Focal EpilepsySeizure

Phase 2

Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy

CompletedNCT06377930

Rapport Therapeutics Inc.Focal Onset Seizures

Start: 2024-10-10End: 2025-09-26Updated: 2026-02-05

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder

Active, not recruitingNCT07046494

Rapport Therapeutics Inc.Bipolar 1 Disorder

Start: 2025-07-25End: 2026-10-01Updated: 2026-08-10

A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

RecruitingNCT07219407

Rapport Therapeutics Inc.Epilepsy, Focal Epilepsy, Focal Onset Seizure +3

Start: 2025-12-15End: 2028-02-03Target: 30Updated: 2026-01-23

Phase 3

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

RecruitingNCT07563881

Rapport Therapeutics Inc.Epilepsy, Focal Epilepsy, Focal Seizure

Start: 2026-06-05End: 2029-09-01Target: 333Updated: 2026-09-01

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

RecruitingNCT07594119

Rapport Therapeutics Inc.Epilepsy, Focal Epilepsy, Focal Seizure

Start: 2026-09-01End: 2029-09-01Target: 312Updated: 2026-09-02